A Phase II, Single-arm, Open-labeled Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms RESCUE
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2018 New trial record